|
1) 西川 亮. 新しい化学療法─テモゾロミド. 脳と神経. 2006; 58: 1035-41
|
|
|
|
2) Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglioma. J Natl Cancer Inst. 1998; 90: 1473-9
|
|
|
|
|
3) Cairncross G, Berkey B, Show E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J Clin Oncol. 2006; 24: 2707-14
|
|
|
|
|
|
4) van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006; 24: 2715-22
|
|
|
|
|
|
5) van den Bent MJ, Taphoorn MJB, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003; 21: 2525-8
|
|
|
|
|
|
6) 西川 亮, 渋井壮一郎, 丸野元彦, 他. 初回再発の退形成性星細胞腫患者に対するテモゾロミド単剤投与の有効性および安全性の検討─多施設共同第II相試験. 癌と化学療法. 2006; 33: 1279-85
|
|
|
|
|
7) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96
|
|
|
|
|
|
8) Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18: 321-4
|
|
|
|
|
|
9) The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001; 19: 509-18
|
|
|
|
|
|
10) Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol. 1999; 17: 2762-71
|
|
|
|
|
|
11) Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas. Predictive impact of 1p/19q loss on response and outcome. Neurology. 2007; 68: 1831-6
|
|
|
|
|
|
12) Ricard D, Kaloshi G, Amil-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007; 61: 484-90
|
|
|
|
|
|
13) Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 1352: 997-1003
|
|
|
|
|
|
14) Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006; 24: 4412-7
|
|
|
|
|
|
15) Chinot O. Schering-Plough Oncology Temodal(R) International Research Update Meeting; 2006 Dec 1-2; Barcelona, Spain
|
|
|
|
|
|
16) Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo din euro-oncologia (GICNO). Brit J Cancer. 2006; 95: 1155-60
|
|
|
|
|
|
17) Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-8
|
|
|
|
|
|
18) Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588-93
|
|
|
|
|
|
19) Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25: 3357-61
|
|
|
|
|
|
20) Su Y-W, Chang M-C, Chiang M-F, et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol. 2005; 71: 315-8
|
|
|
|
|
|
21) De Vita S, De Matteis S, Laurenti L, et al. Secondary Ph＋ acute lymphoblastic leukemia after temozolomide. Ann Hematol. 2005; 84: 760-2
|
|
|
|
|
|
22) Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol. 2006; 8: 280-3
|
|
|
|
|